Anlon Healthcare IPO Details
The key details of Anlon Healthcare’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹121.03 Cr |
| Price Range | ₹86 - ₹91 |
| Retail Quota | 10% |
| QIB Quota | 75% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | NSE and BSE |
| Minimum Quantity | 164 |
| Investment (cut-off price) | ₹14,924 |
| Pre IPO Promotor Holding | 70.26% |
| Post IPO Promotor Holding | Update soon |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Anlon Healthcare IPO Timelines
The IPO process for Anlon Healthcare includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
26/08/2025
Start Date29/08/2025
End Date02/09/2025
Refund Initiation02/09/2025
Credit of Shares to Demat Ac03/09/2025
Listing DateAnlon Healthcare IPO Lot Size
The Anlon Healthcare IPO has a fixed lot size of 164 shares, at an upper price band of ₹91 per share. For retail investors, the minimum application is 164 shares (1 lot) amounting to ₹14,924, while the maximum is 2,132 shares (13 lots) worth ₹1,94,012. For Small HNI (S-HNI) investors, the minimum application is 2,296 shares (14 lots) worth ₹2,08,936, while the maximum is 10,988 shares (67 lots) amounting to ₹9,99,908. Big HNI (B-HNI) investors need to apply for at least 11,152 shares (68 lots), totaling ₹10,14,832.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 164 | ₹14,924 |
| Retail Maximum | 13 | 2132 | ₹1,94,012 |
| S-HNI Minimum | 14 | 2296 | ₹2,08,936 |
| S-HNI Maximum | 67 | 10988 | ₹9,99,908 |
| B-HNI Minimum | 68 | 11152 | ₹10,14,832 |
Anlon Healthcare IPO Subscription Status
The subscription status for Anlon Healthcare IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 1.07x | 10.61x | 47.26x | -- | 7.12x |
IPO Performance on Listing Day
On the listing day (September 03, 2025), Anlon Healthcare made a flat debut on the stock exchange. The stock opened at ₹92, marginally above its issue price of ₹91 with a modest premium of 1.1%. The healthcare company showed brief upward movement during trading, touching a day high of ₹92.50, while finding support near the issue price at ₹90.78. The shares concluded their first trading day at ₹91.73, delivering a minimal gain of 0.8% over the issue price, indicating cautious investor sentiment toward the healthcare sector and a measured market response to this medical services provider.
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹92.00 | ₹91.73 | ₹92.50 | ₹90.78 |
Anlon Healthcare IPO Company Financials
Anlon Healthcare reports robust performance in FY2025 with Total Income of ₹120.46 crores, managing expenses at ₹93.57 crores, and achieving a strong PAT (Profit After Tax) of ₹20.52 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2022 | ₹57.54 | ₹57.64 | -₹0.11 |
| FY 2023 | ₹113.12 | ₹106.13 | ₹5.82 |
| FY 2024 | ₹66.69 | ₹56.94 | ₹9.66 |
| FY 2025 | ₹120.46 | ₹93.57 | ₹20.52 |
About Company
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company specializing in the production of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs). These products are used in formulations for human and veterinary medicines, nutraceuticals, and personal care products. The company adheres to both Indian and international pharmacopeia standards, including IP, BP, EP, JP, and USP. Alongside standard manufacturing, Anlon offers custom manufacturing services for complex chemicals, focusing on high purity and low impurity levels tailored to client specifications.
Anlon has established a strong regulatory presence, with Drug Master File (DMF) approvals from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid, and is currently pursuing DMF filings for Ketoprofen and Dexketoprofen Trometamol. Its product portfolio includes 65 commercialized products, 28 at the pilot stage, and 49 in laboratory testing. The company emphasizes stringent quality control through advanced testing and continuous process improvements, supported by four laboratories and a 34-member team, of which 24 are science graduates.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2013 | Pharmaceuticals | Punit Rasadia |
Know Before Investing
Anlon Healthcare IPO Strengths
- Anlon Healthcare manufactures a wide range of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs, personal care ingredients, and veterinary APIs, enhancing market reach and growth potential.
- Anlon is led by experienced promoters and a skilled management team with a proven track record in pharmaceutical manufacturing and business growth.
- The company has obtained important global regulatory approvals and filed numerous DMFs across various regions, enabling export capabilities and market expansion.
- Anlon is expanding its manufacturing facility to scale up production capabilities, which supports future revenue growth and operational scalability.
- Strict regulatory standards, complex manufacturing processes, and high capital requirements create barriers to entry, reducing competition and protecting market share.
- With several commercialized products, pilot projects, and extensive R&D efforts, Anlon is well positioned to introduce innovative pharmaceuticals and nutraceuticals.
- Anlon is developing custom manufacturing capabilities for novel and high-purity compounds, tapping into niche markets with higher value propositions.
Anlon Healthcare IPO Risks
- The company’s ability to manufacture and export pharmaceutical products is contingent on timely receipt and maintenance of various regulatory approvals. Delays or refusals could disrupt business operations.
- Anlon Healthcare is exposed to fluctuations in prices of raw materials and chemicals used in production, which may impact cost structures and profitability.
- The pharmaceutical intermediates and APIs market is highly competitive with both domestic and international players. Price pressures and losing market share to competitors can affect margins.
- A substantial portion of revenue may come from a limited number of clients. Loss or reduced orders from key customers could materially affect business revenue.
- Challenges such as equipment breakdowns, quality control failures, or supply chain disruptions could delay production and delivery schedules.
- Since Anlon exports products internationally, currency fluctuations can impact revenue and profitability.
- The pharmaceutical sector involves strict environmental, health, and safety regulations. Non-compliance or changes in regulations may increase operational costs.
Swot Analysis for Anlon Healthcare IPO
Strengths
Research-Driven Manufacturing, In-House R&D and Quality Control, Global Recognition and Compliance
Weaknesses
Single Manufacturing Facility Dependence, Revenue Concentration Risk, Limited Diversification
Opportunities
Growing Global API Demand, Expansion of Product Pipeline, Government and Regulatory Push
Threats
Stringent Regulatory Environment, Raw Material and Input Volatility, Geopolitical and Trade Risks
Company Details
Anlon Healthcare Ltd.
101/102, Silvercoin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot –360 005, Gujarat, India
Phone: +91 281 2562538
Email: cs@anloncro.com
Website: http://www.anlon.in/
IPO Registar Details
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: ahl.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
FAQs
The key objectives of Anlon Healthcare IPO are:
- Funding capital expenditure requirements for Proposed Expansion
- Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan) availed by the Company
- Funding the working capital requirements of the Company
- General corporate purposes
Interactive Financial Services Ltd. is the book-running lead managers for the Anlon Healthcare IPO.
Anlon Healthcare exhibits compelling growth potential with a robust portfolio of 65 commercial products, 28 in pilot stage, and another 49 in R&D. FY2024 results reflect operational progress with revenue of ₹66.69 crore, PAT of ₹9.66 crore, and EPS of ₹6.68. While early-stage profitability and reliance on a single manufacturing facility highlight execution and concentration risks, the company’s expanding product pipeline and improving margins point to significant upside.
The issue price for the Anlon Healthcare IPO is set between ₹86 to ₹91 per share.
To invest in one lot of Anlon Healthcare IPO, you need ₹14,104 at the lower price band (₹86 per share) or ₹14,924 at the upper price band (₹91 per share) for a lot size of 164 shares.
Anlon Healthcare IPO shares are scheduled to be listed on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on September 3, 2025.
Refund/unblocking of funds for Anlon Healthcare IPO will begin on September 2, 2025. ASBA/UPI blocks will be removed within 1 working day.
You can sell shares your Anlon Healthcare IPO shares on listing day (September 3, 2025) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.